ArticleCancer2023
Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
Article in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 22 citations in OpenAlex.
- SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.Breast cancer research and treatment · 2024Trial
- Managing capivasertib-induced hyperglycemia: a report of 3 cases.JCEM case reports · 2026Article
- MicroRNAs and Alarmins in Cardio-Oncology: Biomarkers and Therapeutic Implications in Skin and Breast Cancer.International journal of molecular sciences · 2026Review
- SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.International journal of molecular sciences · 2026Article
- Article
- Biochemical landscape of breast cancer: integrating serum markers with clinical prognosis and staging.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.Cancer research communications · 2026Article
- FOXM1 Signaling Network Transcriptionally Upregulates Expression of Proteins Involved in Mitotic Progression to Induce High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast Cancer.International journal of molecular sciences · 2026Article
- Surfactant-enhanced emulsification liquid-liquid microextraction combined with sweeping micellar electrokinetic chromatography-tandem mass spectrometry for therapeutic drug monitoring of alpelisib and fulvestrant in human plasma.Analytical and bioanalytical chemistry · 2026Article
- Article
- Etiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients: A Retrospective Analysis.Cancers · 2025Article
- Glucagon-like peptide-1 receptor agonists inhibit the progression of malignant pleural effusion in obese mice by regulating the metabolism of pleural effusion.Journal of translational medicine · 2025Article
- Dynamics of hyperglycemia of patients treated with alpelisib: exploratory interim analysis of ITACA trial.The oncologist · 2025Article
- Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling.Frontiers in oncology · 2025Article
- Obesity, overweight and breast cancer: new clinical data and implications for practice.Frontiers in oncology · 2025Review
- The effects of hsa-mir-26a-5p on cell proliferation, migration, and PI3K inhibitor sensitivity in metformin-resistant triple negative breast cancer cells.Turkish journal of biology = Turk biyoloji dergisi · 2025Article
- Medication-Induced Hyperglycemia and Diabetes Mellitus: A Review of Current Literature and Practical Management Strategies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists' practices.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study.Heliyon · 2024Article
- Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.Cancer discovery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe combination of fulvestrant with alpelisib, a PI3K inhibitor, improves progression-free survival in metastatic hormone receptor-positive, PIK3CA-mutant breast cancer. This study describes the incidence, risk factors, and treatment of alpelisib-associated hyperglycemia.
methodsPatients with metastatic breast cancer who received alpelisib from 2013 to 2021 at Memorial Sloan Kettering Cancer Center were included in this retrospective study. Alpelisib prescription dates and patient/tumor characteristics were abstracted from medical records. Risk factors associated with hyperglycemia and alpelisib dose reduction/discontinuation were evaluated using Pearson's χ
resultsAmong 247 patients, baseline median body mass index was 25.4 kg/m
conclusionsRates of hyperglycemia among patients treated with alpelisib as standard care were significantly higher than patients treated on clinical trials. Elevated baseline HbA1c is associated with alpelisib-induced hyperglycemia and requiring dose modification. Optimization of glycemic status before alpelisib initiation should become routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.